Purple Biotech (PPBT) Consolidated Net Income (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Consolidated Net Income data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income rose 67.05% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $27.8 million, a 311.98% increase from a year earlier, with the FY2025 full-year figure at -$26.4 million, down 261.55% from the prior year.
• Consolidated Net Income for Q1 2026 stood at $2.2 million, down from $23.2 million in the prior quarter.
• Over the last five years, Consolidated Net Income for PPBT reached as high as $23.2 million in Q4 2025 and fell as low as $629000.0 in Q4 2024.
• Historically, Consolidated Net Income has averaged $4.8 million across 5 years, with a median of $4.4 million in 2024.
• Across the five-year window, Consolidated Net Income jumped 172600.0% in 2022 and plunged 89.98% in 2024, its largest moves.
• Year by year, Consolidated Net Income stood at $6.0 million in 2022, then gained by 3.91% to $6.3 million in 2023, then plunged by 89.98% to $629000.0 in 2024, then jumped by 3580.92% to $23.2 million in 2025, then sank by 90.5% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were $2.2 million in Q1 2026, $23.2 million in Q4 2025, and $1.2 million in Q3 2025.